Wintherix announces WX04554 molecule can cause bone healing

Links shared publicly online about this topic.

872
total visits

Wintherix announces WX04554 molecule can cause bone healing

Wintherix, LLC, a privately held biotechnology company focusing on bone healing and regenerative medicine, today announced that WX04554, a potent small molecule activator of the Wnt pathway, has been designated as a lead drug for clinical development in bone healing and repair indications.

View full resource at news-medical.net

Tags: Bone, Drug, Biotech